Sign up to save your podcasts
Or
Share Reducing Cardiovascular Risk with PCSK9 Inhibitors: Addressing Challenges and Improving Outcomes
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Reducing Cardiovascular Risk with PCSK9 Inhibitors: Addressing Challenges and Improving Outcomes
CME credits: 0.50
Valid until: 31-05-2023
Claim your CME credit at https://reachmd.com/programs/cme/reducing-cardiovascular-risk-with-pcsk9-inhibitors-addressing-challenges-and-improving-outcomes/13698/
Two lipid experts will 1) provide an overview of the landscape of nonstatin, LDL-C-lowering therapy, 2) explain current guideline recommendations, 3) describe the evidence with ezetimibe and PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD), 4) discuss cardiovascular risk reduction with PCSK9 inhibitors in a variety of very high risk ASCVD patient populations, and 5) emphasize the need to incorporate PCSK9 inhibition early in acute coronary syndrome patients to facilitate best patient outcomes.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.50
Valid until: 31-05-2023
Claim your CME credit at https://reachmd.com/programs/cme/reducing-cardiovascular-risk-with-pcsk9-inhibitors-addressing-challenges-and-improving-outcomes/13698/
Two lipid experts will 1) provide an overview of the landscape of nonstatin, LDL-C-lowering therapy, 2) explain current guideline recommendations, 3) describe the evidence with ezetimibe and PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD), 4) discuss cardiovascular risk reduction with PCSK9 inhibitors in a variety of very high risk ASCVD patient populations, and 5) emphasize the need to incorporate PCSK9 inhibition early in acute coronary syndrome patients to facilitate best patient outcomes.
=